Invivyd Announces Superior Safety Results From LIBERTY Phase 3 Study
The company reported Phase 3 topline results showing VYD2311 demonstrated safety and tolerability clinically superior to mRNA vaccines. This milestone supports the planned Biologics License Application submission.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed